An early study illustrated that the loss of B cells (anti-CD20) significantly enhanced responses to cisplatin, carboplatin, and paclitaxel through the increase of tumor CD4+ and CD8+ T cell infiltration (115). This evidence concerns the gene CD4 and neoplasm.